BackRedhill Biopharma Overview

Redhill Biopharma Receivables

Latest receivables for RDHL: $2.5M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$2.48M
30.48% YoYΔ $-1.09M vs prior year quarter

Peer average

Loading

Redhill Biopharma Receivables History

Loading

Redhill Biopharma vs. peers: Receivables Comparison

Loading

Redhill Biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Redhill Biopharma (RDHL) FAQ

As of the most recent data (December 2025), RDHL shows a receivables of $2.5M. That compares with $3.6M in the prior-year period — down 30.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RDHL's receivables is now $2.5M (was $3.6M) — a 30.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Redhill Biopharma is outperforming or lagging.

Tracking RDHL's receivables over time shows whether Redhill Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $2.5M That compares with $3.6M in the prior-year period — down 30.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Redhill Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $2.5M) with ownership activity and broader fundamentals.

Redhill Biopharma's receivables is $2.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.